@article{3220660,
    title = "Fertility outcomes after treatment with intraperitoneal chemotherapy",
    author = "Papageorgiou, D. and Diakosavvas, M. and Angelou, K. and Kathopoulis, N. and Voros, C. and Zachariou, E. and Papadatou, K. and Papapanagiotou, I.K. and Papakonstantinou, K.",
    journal = "The journal of obstetrics and gynaecology research",
    year = "2022",
    publisher = "Taylor and Francis Ltd.",
    doi = "10.1080/01443615.2022.2055453",
    abstract = "Intraperitoneal chemotherapy (IPC) administration has been added to the therapeutic protocols of cancers, confined to the abdominal cavity. Since, a survival benefit in patients treated with adjuvant IPC has been demonstrated, fertility questions are raised in these patients. A comprehensive search of the English literature of PubMed/MEDLINE, EmBase and Google Scholar databases was conducted, from their inception until April 2021, following the MOOSE guidelines. Twelve out of 473 studies were included in the final review and analysis. After treatment with IPC for peritoneal carcinomatosis, 19 women, who underwent fertility-sparing surgery, with 20 successful pregnancies were reported. The mean interval time between IPC and pregnancy was 38.4 months (range 9–168 months). In 16 cases, conception was spontaneous, three required in vitro fertilisation, whereas one pregnancy was achieved through intrauterine insemination. Mean disease-free survival was 76 months (range 24–177 months). Childbearing is a feasible approach in selected patients, after treatment with IPC. When future pregnancy is desirable, a multidisciplinary team of surgeons, gynaecologists, oncologists and reproductive specialists is required, to inform the patient thoroughly about the fertility preservation alternatives, without endangering patient’s survival. © 2022 Informa UK Limited, trading as Taylor & Francis Group."
}